Some common reasons include: Insurance formulary changes : Your insurance may no longer cover your current GLP-1 or may start preferring a different brand-name option
As with other agents that cause significant weight loss or gastrointestinal fluid losses, there are theoretical class-related risks that warrant attention, including gallbladder disease (cholelithiasis and cholecystitis have been reported with GLP-1 receptor agonists), and dehydration or acute kidney injury in the context of persistent vomiting or diarrhoea
The wound healing cascade and GHK-Cu: Normal wound healing occurs in four overlapping phases: Hemostasis clotting Inflammation immune cell recruitment Proliferation new tissue formation Remodeling scar maturation GHK-Cu appears to favorably influence phases 2, 3, and 4 simultaneously: In the inflammatory phase , it reduces pro-inflammatory cytokines (IL-6, TNF-) while preserving necessary immune signaling In the proliferative phase , it stimulates keratinocyte migration and fibroblast proliferation, accelerating epithelial coverage In the remodeling phase , it promotes type I collagen deposition over type III (scar) collagen, leading to better scar outcomes This multi-phase tissue repair activity makes GHK-Cu a compound of interest when studied alongside other regenerative peptides
It is prescribed to patients with chronic obesity or overweight individuals living with a weight-associated health condition
Let me go over to my computer to show you something
MHRA/GOV.UK: First GLP-1 tablet for weight loss approved in the UK
